Zobrazeno 1 - 10
of 388
pro vyhledávání: '"Constantin A. Dasanu"'
Autor:
Jorge J Castillo, Edwin C Kingsley, Mohit Narang, Habte A Yimer, Constantin A Dasanu, Jason M Melear, Morton Coleman, Charles M Farber, Jonah Shulman, Emily H Mantovani, Xiaowei Zhang, Aileen Cohen, Jane Huang
Publikováno v:
eJHaem, Vol 4, Iss 1, Pp 301-304 (2023)
Externí odkaz:
https://doaj.org/article/61318e5dc11945ce8ecb239e81fc2c4b
Publikováno v:
Expert opinion on pharmacotherapy. 23(11)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dda54a56e8e61fb9ae927e204527c6c
https://pubmed.ncbi.nlm.nih.gov/35703589
https://pubmed.ncbi.nlm.nih.gov/35703589
Publikováno v:
Journal of Oncology Pharmacy Practice. :107815522311782
Objective This paper reviews comprehensively the most relevant data on single-agent and combination therapies for advanced colorectal cancer with inherited and acquired microsatellite instability (MSI). Data Sources We performed a systematic search o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::18954eba94b6dd275c844fc5764373e1
https://doi.org/10.1177/10781552231178293
https://doi.org/10.1177/10781552231178293
Publikováno v:
Journal of Oncology Pharmacy Practice. 28:722-724
Introduction Clinical indications of immune checkpoint inhibitors have expanded to a variety of malignancies. Nearly 50% of patients with advanced cutaneous squamous cell carcinoma, respond to the programmed-death 1 inhibitor cemiplimab. To date, ins
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffdc52c54efbad586aa62fb1d58d639c
https://doi.org/10.1177/10781552211060523
https://doi.org/10.1177/10781552211060523
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 28(8)
Introduction Zanubrutinib is a second generation, irreversible small-molecule Bruton tyrosine kinase inhibitor (BTK) approved for the treatment of Waldenström's macroglobulinemia, mantle cell lymphoma, and marginal zone lymphoma. As a class, BTKs ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36da5db5caef3d2f6f25bfa9c34366a8
https://pubmed.ncbi.nlm.nih.gov/35306909
https://pubmed.ncbi.nlm.nih.gov/35306909
Publikováno v:
Journal of Oncology Pharmacy Practice. 28:442-444
Introduction Bruton tyrosine kinase inhibitors represent important tools in the therapeutic armamentarium against chronic lymphocytic leukemia (CLL) and other B-lymphoproliferative disorders. Case Report We describe herein a unique 65-year-old patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05587f40d8f81f8f576564e324d7f66c
https://doi.org/10.1177/10781552211029703
https://doi.org/10.1177/10781552211029703
Publikováno v:
Journal of Oncology Pharmacy Practice. 27:453-456
Introduction Clinical indications of immune checkpoint inhibitors have expanded to a variety of malignancies. Approximately one in six patients with hepatocellular carcinoma respond to programmed death 1 inhibitors nivolumab and pembrolizumab. Case r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30eee7c471ec8fa0cb1833bbeed948d4
https://doi.org/10.1177/1078155220929967
https://doi.org/10.1177/1078155220929967
Autor:
Steven C. Plaxe, Varun Gupta, Juliana Alvarez-Argote, Mayumi Grover, Constantin A Dasanu, Iliana M Popescu
Publikováno v:
Journal of Oncology Pharmacy Practice. 26:1516-1519
IntroductionUse of immune checkpoint inhibitors has expanded to a variety of malignancies including hepatocellular carcinoma, where nivolumab and pembrolizumab have shown durable responses in approximately a sixth of patients.Case reportWe report her
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87031eb61d3e5047e91fa9f15391f867
https://doi.org/10.1177/1078155220903367
https://doi.org/10.1177/1078155220903367
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 28(4)
Introduction Although rare, Kaposi sarcoma is the most common malignant neoplasm associated with human immunodeficiency virus (HIV) infection. Several agents have now been approved in the treatment of this malignancy and are used with varying degrees
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73b2cbcef29070d0bb8ceeead2be28f9
https://pubmed.ncbi.nlm.nih.gov/35037777
https://pubmed.ncbi.nlm.nih.gov/35037777
Publikováno v:
Journal of Oncology Pharmacy Practice. :107815522311544
Introduction Combined immune checkpoint inhibitor therapy has been successfully used in the treatment of several malignancies. Adverse effects with the combination therapy may be more severe than the ones seen with single immune checkpoint inhibitors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::76dc265dfafc683bfa6f885d28219468
https://doi.org/10.1177/10781552231154460
https://doi.org/10.1177/10781552231154460